Navigation Links
Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
Date:1/10/2014

n general, these patients are severely ill and have a great medical need for a topical therapy that may better manage their symptoms.  In the second quarter of 2014, Rigel will initiate a Phase 2 study of R348 in patients with dry eye as a result of primary GvHD.

R118, AMPK Activator for Intermittent Claudication
Intermittent claudication (IC) refers to the muscle pain associated with peripheral artery disease (PAD) caused by either atherosclerosis or inflammation.  Patients with IC have difficulty with simple activities, like walking, and current therapies do not provide sufficient relief.  IC affects more than 5% of the population age 65 or older, but anyone with PAD may also suffer the effects of IC.   Preclinical evaluation of R118, an AMPK activator, has shown it to be a central regulator of lipid and metabolic activity and capable of increasing muscle endurance.  Rigel plans to initiate a Phase 1 trial of R118 in patients with IC in the first half of 2014.

Partnerships
In addition to the five clinical programs noted above, Rigel also has products in varying stages of preclinical and clinical development with three pharmaceutical partners.  

In June 2012, Rigel and AstraZeneca announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor as a potential treatment for asthma.  AstraZeneca is responsible for the development of R256.  It's continued efforts to bring R256 into first-in-human studies triggered the $5.75 million milestone payment to Rigel.

Partners BerGenBio and Daiichi Sankyo are developing Rigel's Axl Kinase inhibitor and a Ubiquitin Ligase inhibitor, respectively, for their potential safety and efficacy in treating various cancers.  Both of these molecules are currently in Phase 1 clinical development.

Financial Update
Rigel ended 2013 with approxim
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel to Present at Oppenheimer Healthcare Conference
2. Rigel Announces Third Quarter 2013 Financial Results
3. Rigel Provides Pipeline Update
4. Rigel to Present at Stifel Healthcare Conference
5. Rigel To Focus On ITP, DLE And Dry Eye
6. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
7. Rigel Announces Second Quarter 2013 Financial Results
8. Rigel Will Resume Responsibility for Fostamatinib Program
9. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
10. Rigel Announces First Quarter 2013 Financial Results
11. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... 2014 ApolloDx™ today announced it will unveil ... special event at the company,s office in ... 2014. The event, which will start at 10:00 a.m., ... www.apollodx.com .    "We believe our mobile ... Bauer , Co-Founder and Managing Partner of ApolloDx. In ...
(Date:8/20/2014)... SAN DIEGO , Aug. 20, 2014 ... molecular diagnostics, announced today that results from two clinical ... (IPV) conference for the Company,s urine-based diagnostic test for ... (HPV). The IPV conference is scheduled to take place ... st to 25 th . Additionally, a new ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... 2007 /PRNewswire-USNewswire/ -- The,following statement may be attributed ... Medical Research (CAMR): , "In the face of ... the stroke of his veto pen deliberately to ... well as endanger,the future health and well being ...
... - Elixir,Pharmaceuticals, Inc., announced today the publication ... (mitiglinide calcium,hydrate) monotherapy, or combination therapy with ... meals. The data were,published in the Abstract ... Scientific Sessions in Chicago, Illinois.,Glufast is an ...
Cached Medicine Technology:President Bush Ignores America's Plea for Support of Stem Cell,Research 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5
(Date:8/20/2014)... approach to treating cancer - using Botox. A study ... Translational Medicine shows that cancer growth could be ... are linked to cancer stem cells. The approach thus ... treatment cheap, safe and efficient. The researchers have thus ... start testing on humans. , The nervous system is ...
(Date:8/20/2014)... August 20, 2014 Quincy Bioscience, a ... 500|5000 list of the fastest growing private companies ... Ranking at No. 2,941, Quincy Bioscience is honored again ... the United States. , Quincy Bioscience is manufacturer of ... – a protein originally discovered in jellyfish and clinically ...
(Date:8/20/2014)... DALLAS (PRWEB) August 20, 2014 Caddis ... track records of any healthcare real estate company in ... of medical assets valued at $500 million, including more ... of that significant growth, including expansions into new geographic ... expanded capabilities, company executives are pleased to announce an ...
(Date:8/20/2014)... Beach, Florida (PRWEB) August 20, 2014 ... Florida, with the help of their experienced surgeons trained ... of patients to regain their lost or inaccurate vision. ... for performing Lasik surgery is making it possible for ... aging disease which occurs normally in people in the ...
(Date:8/20/2014)... Antonio, TX (PRWEB) August 20, 2014 Texas ... their new study. The study will help test the effectiveness ... who suffer from high cholesterol may be eligible to participate ... too much cholesterol in the blood can lead to cardiovascular ... States. Lowering cholesterol can help reduce the risk of heart ...
Breaking Medicine News(10 mins):Health News:Treating gastric cancer -- with Botox 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2Health News:Texas Medical Research Associates Announce New Study 2
... Income in Company History, BELLEVUE, Wash., Feb. 6 ... provider of health, beauty, vision, and,pharmacy products, today announced ... ended December 30, 2007. The company reported,quarterly net sales ... $0.00,per share. The company achieved record gross margins in ...
... of Mobility Program Helps Eden Home Resident regain mobility and,Be ... is a "sweetheart with a sweet tooth" say his friends ... a borrowed power wheelchair,from delivering mail at the facility where ... self-professed "chocoholic." To keep him on the,go, The SCOOTER Store ...
... 6 The Juvenile,Products Manufacturers Association (JPMA), which ... United States, stands by the,scientific research indicating that ... to fall victim to scare tactics., There ... Bisphenol-A, a,material used to make tough, shatter-resistant polycarbonate ...
... Va., Feb. 6 The HealthCentral,Network, Inc. ... accomplished dermatologist, cosmetic surgeon and author, is,joining the ... Sundaram is the author of Face Value: The ... It [Rodale], which was honored by,the National Press ...
... Medical,Innovations, Inc. (Amex: IMA ), a leading ... consumer and professional markets, announced,today that it will ... being held February 11 through 13, 2008 at ... Zwanziger, Chief Executive Officer, and Jon Russell,Vice President, ...
... saves lives. It saves money. And it,s time., ... of the,growing momentum for electronic prescribing (e-prescribing), Health ... before the,Senate Finance Committee that e-prescribing standards and ... adopt the technology in Medicare., When questioned ...
Cached Medicine News:Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 2Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 3Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 4Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 5Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 6Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 7Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 8Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 9Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 10Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 11Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 12Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 13Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 14Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 15Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 16Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 17Health News:The SCOOTER Store Donates Power Wheelchair to New Braunfels Car Crash Victim 2Health News:JPMA on the Safety of Baby Bottles 2Health News:Prominent Cosmetic Dermatologist and Author Joins MySkinCareConnection.com 2Health News:Prominent Cosmetic Dermatologist and Author Joins MySkinCareConnection.com 3Health News:Inverness Medical Innovations to Present at 2008 UBS Global Healthcare Services Conference on February 13, 2008 2Health News:PCMA Applauds Secretary Leavitt's Support for Requiring E-Prescribing in Medicare 2Health News:PCMA Applauds Secretary Leavitt's Support for Requiring E-Prescribing in Medicare 3
20L...
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
... includes fixed-volume, adjustable-volume, and multichannel models ... Research pro Pipette. Designed with a ... pipettes have earned a worldwide reputation ... with original Eppendorf pipette tips, they ...
Medicine Products: